Skip to main content
. 2018 Jul 10;9(53):30092–30105. doi: 10.18632/oncotarget.25723

Figure 6. Pharmacological inhibition of TRKA in vitro and in vivo.

Figure 6

(A) Western blot of NGF/TRKA signaling inhibition with entrectinib. TF-1 cells were incubated with varying concentrations of entrectinib (0-100nM) for 1 hour prior to 15 minutes of NGF (100ng/mL) stimulation. (B) SPADE visual summary of CyTOF single cell protein data for TF-1 cells treated with NGF (100ng/mL for 15 minutes) and entrectinib (300nM for 2 hours prior to NGF stimulation). (C) Viable cell numbers of CMK, K562, and (D) TF-1 (under different culture conditions) were recorded after 72 of incubation with increasing doses of entrectinib (0.1-3000nM) and normalized to their corresponding untreated controls. (E) Summary of tumor burden in mice engrafted with TF-1 leukemia after 3 weeks of entrectinib therapy.